Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem reported strong FY2026 results with standalone revenue of Rs 4,963 million, up 35% from Rs 3,664 million in FY2025. Net profit after tax surged to Rs 391 million from just Rs 3 million in the previous year. Consolidated revenue stood at Rs 5,059 million with PAT of Rs 421 million versus Rs 57 million in FY2025. The Board recommended a final dividend of Rs 2 per share (20%) for shareholder approval. New auditors were appointed - M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech as Internal Auditor for FY2026-27. Statutory auditors NDJ & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.
The company showed exceptional turnaround with massive PAT growth from a low base, indicating strong operational improvement. Revenue growth of 35% demonstrates solid business momentum. Clean audit reports and dividend declaration are positive signals for shareholders.